Atara Biotherapeutics Announces Changes to Its Board of Directors
20 December 2022 - 12:00AM
Business Wire
Atara Biotherapeutics, Inc. (Nasdaq: ATRA) today announced that
Carol Gallagher will assume the role of Chair of the Board of
Directors, replacing Ron Renaud, who is stepping down to focus on
his new position as Managing Director at Bain Capital Life
Sciences.
“Since 2020, I have had the privilege of serving on Atara’s
Board of Directors and witnessing firsthand the progress across its
pipeline of potentially transformative therapies,” said Ron Renaud.
“Atara has a best-in-class team of visionaries who I wish success
on their journey to transform the lives of patients with high unmet
medical need. I have worked alongside Carol for years and have full
confidence that she will help drive Atara’s growth to new heights
as Chair.”
Carol Gallagher, Pharm.D. is a venture partner in the life
sciences practice of New Enterprise Associates and an experienced
public company director. She has served as a Director at Atara
since 2013 and as a member of both the Compensation and Nominating
and Corporate Governance Committees. Gallagher was formerly the
President and CEO of Calistoga Pharmaceuticals and has held
commercial and drug development roles within Eli Lilly, Amgen,
Agouron, Pfizer and Biogen Idec.
Atara also announced that after four years of service, Roy
Baynes, M.D., Ph.D., has decided to step down from Atara’s Board of
Directors to pursue other external opportunities following his
retirement from Merck.
“On behalf of Atara and its Board of Directors, I want to
express my gratitude to both Ron and Roy for their dedicated
service to our company and its shareholders,” said Pascal Touchon,
President and Chief Executive Officer of Atara. “We look forward to
entering an exciting year under Carol’s Board stewardship as we
progress toward realizing the full potential of our EBV T-cell
platform across multiple therapeutic areas.”
About Atara Biotherapeutics, Inc.
Atara Biotherapeutics, Inc. (@Atarabio) is a pioneer in T-cell
immunotherapy leveraging its novel allogeneic EBV T-cell platform
to develop transformative therapies for patients with serious
diseases including solid tumors, hematologic cancers and autoimmune
disease. With our lead program receiving marketing authorization in
Europe, Atara is the most advanced allogeneic T-cell immunotherapy
company and intends to rapidly deliver off-the-shelf treatments to
patients with high unmet medical need. Our platform leverages the
unique biology of EBV T cells and has the capability to treat a
wide range of EBV-associated diseases, or other serious diseases
through incorporation of engineered CARs (chimeric antigen
receptors) or TCRs (T-cell receptors). Atara is applying this one
platform, which does not require TCR or HLA gene editing, to create
a robust pipeline including: tab-cel for Epstein-Barr virus
positive post-transplant lymphoproliferative disease (EBV+ PTLD)
and other EBV-driven diseases; ATA188, a T-cell immunotherapy
targeting EBV antigens as a potential treatment for multiple
sclerosis; and multiple next-generation chimeric antigen receptor
T-cell (CAR-T) immunotherapies for both solid tumors and
hematologic malignancies. Improving patients’ lives is our mission
and we will never stop working to bring transformative therapies to
those in need. Atara is headquartered in Southern California. For
additional information about the company, please visit atarabio.com
and follow us on Twitter and LinkedIn.
Forward-Looking Statements
This press release contains or may imply “forward-looking
statements” within the meaning of Section 27A of the Securities Act
of 1933 and Section 21E of the Securities Exchange Act of 1934. For
example, forward-looking statements include statements regarding
Atara’s pipeline and platform, and the development, timing,
progress, characteristics and benefits of Atara’s pipeline and
platform. Because such statements deal with future events and are
based on Atara’s current expectations, they are subject to various
risks and uncertainties and actual results, performance or
achievements of Atara could differ materially from those described
in or implied by the statements in this press release. These
forward-looking statements are subject to risks and uncertainties,
including, without limitation, risks and uncertainties associated
with the costly and time-consuming pharmaceutical product
development process and the uncertainty of clinical success; the
COVID-19 pandemic, which may significantly impact (i) our business,
research, clinical development plans and operations, including our
operations in Southern California and Denver and at our clinical
trial sites, as well as the business or operations of our
third-party manufacturer, contract research organizations or other
third parties with whom we conduct business, (ii) our ability to
access capital, and (iii) the value of our common stock; the
sufficiency of Atara’s cash resources and need for additional
capital; and other risks and uncertainties affecting Atara’s and
its development programs, including those discussed in Atara’s
filings with the Securities and Exchange Commission (SEC),
including in the “Risk Factors” and “Management’s Discussion and
Analysis of Financial Condition and Results of Operations” sections
of the Company’s most recently filed periodic reports on Form 10-K
and Form 10-Q and subsequent filings and in the documents
incorporated by reference therein. Except as otherwise required by
law, Atara disclaims any intention or obligation to update or
revise any forward-looking statements, which speak only as of the
date hereof, whether as a result of new information, future events
or circumstances or otherwise.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20221218005056/en/
INVESTORS & MEDIA: Investors Eric Hyllengren
805-395-9669 ehyllengren@atarabio.com
Media Alex Chapman 805-456-4772 achapman@atarabio.com
Atara Biotherapeutics (NASDAQ:ATRA)
Historical Stock Chart
From Mar 2024 to Apr 2024
Atara Biotherapeutics (NASDAQ:ATRA)
Historical Stock Chart
From Apr 2023 to Apr 2024